BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | ||
England and Wales High Court (Patents Court) Decisions |
||
You are here: BAILII >> Databases >> England and Wales High Court (Patents Court) Decisions >> Neurim Pharmaceuticals (1991) Ltd & Anor v Generics (UK) Ltd (t/a Viatris) [2022] EWHC 272 (Pat) (10 February 2022) URL: http://www.bailii.org/ew/cases/EWHC/Patents/2022/272.html Cite as: [2022] EWHC 272 (Pat) |
[New search] [Printable PDF version] [Help]
Case No. HP-2021-000021 |
BUSINESS AND PROPERTY COURTS OF ENGLAND AND WALES
INTELLECTUAL PROPERTY LIST (ChD)
PATENTS COURT
Fetter Lane, London, EC4A 1NL |
||
B e f o r e :
____________________
(1) NEURIM PHARMACEUTICALS (1991) LIMITED (2) FLYNN PHARMA LIMITED |
Claimants |
|
- and - |
||
(1) GENERICS (UK) LIMITED T/A VIATRIS (2) VIATRIS UK HEALTHCARE LIMITED |
Defendants |
____________________
Piers Acland QC, Adam Gamsa and Daniel Piccinin (instructed by Taylor Wessing LLP) for the Defendants
Decided on the papers, without oral argument
____________________
Crown Copyright ©
Mr Justice Marcus Smith
i) The Main Judgment (described at [7] of the Judgment). The Main Judgment was the outcome of a trial that I heard over a number of days at the end of 2020 (the Trial).
ii) The Consequentials Judgment (described at [10] of the Judgment).
"In the unusual circumstances of this situation, I think I must tread especially carefully. Mr Acland [counsel for Mylan] accepts today – there can be no ambiguity about this, and Mylan will be held to it – that this can go back to Marcus Smith J. That seems to me to be a fair, proportionate and judicially appropriate way to proceed because if he decides, it being a decision for him and after he receives submissions, to adopt what he did before, he will be adopting his own findings, his own words and his own judgment. It will also eliminate the possibility of another judge having to deal with something uncomfortably halfway between an appeal and a fresh trial, and it best addresses the problem, which Mr Acland acknowledges, that the materials to which Mylan wants to refer include evidence from Professor Morgan, whom Marcus Smith J has the unique advantage of having heard at the first trial."